HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1311-1319

  Su, Feng ^a   Grijalva, Victor ^a   Navab, Kaveh ^a   Ganapathy, Ekambaram ^a   Meriwether, David ^a   Imaizumi, Satoshi ^a,c   Navab, Mohamad ^a   Fogelman, Alan M ^a   Reddy, Srinivasa T ^a,b   Farias Eisner, Robin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; APOLIPOPROTEIN A1; CLUSTERIN; HIGH DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; PEPTIDOMIMETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLON ADENOCARCINOMA; COLON CANCER; COLON POLYPOSIS; DISEASE COURSE; DISEASE MODEL; FEMALE; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN A-I; CLUSTERIN; COLON; COLONIC NEOPLASMS; FEMALE; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MICE; MOLECULAR MIMICRY; NEOPLASM TRANSPLANTATION; PEPTIDES;

EID: 84862556964     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0905     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. 2010. CA Cancer J Clin 2010;60:277-300.
2. Vámosi-Nagy I, Köves I. Endoscopic diagnostics of colorectal cancers. Acta Chir Hung 1992-1993;33:149-56.
3. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009;50:S145-9.
4. Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 2000;153:263-72. (Pubitemid 32120325)
5. Kapur NK, Ashen D, Blumenthal RS. High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag 2008;4:39-57. (Pubitemid 351460845)
6. Shah PK. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr Opin Cardiol 2010;25: 603-8.
7. Haseeb Jafri, Alawi A, Alsheikh-Ali Richard H, KarasJafri H, Alsheikh- Ali Alawi A, Karas Richard H. High-density lipoprotein cholesterol levels are inversely associated with cancer risk. Circulation 2009;120: S406.
8. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjønneland A, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14: 755-67. (Pubitemid 350074064)
9. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calliqaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2001;60:1094-102.
10. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
11. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010;30:164-8.
12. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003 14;100:12343-8.
13. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96. (Pubitemid 41739936)
14. Su F, Lang J, Kumar A, Ng C, Heieh B, Suchard MA, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007;16:369-75.
15. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008;199:215-23.
16. Nossov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009;200:639.e1-5.
17. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 2010;107:19997-20002.
18. Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011;52:1200-10.
19. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 2007;433:1-25.
20. Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol 1995;18:139-46. (Pubitemid 26016519)
21. Liao HF, Chen YY, Liu JJ, Hsu ML, Shieh HJ, Liao HJ, et al. Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis. J Agric Food Chem 2003;51: 7907-12.
22. Chang KH, Liao HF, Chang HH, Chen YY, Yu MC, Chou CJ, et al. Inhibitory effect of tetrandrine on pulmonary metastases in CT26 colorectal adenocarcinoma-bearing BALB/c mice. Am J Clin Med 2004;32:863-72.
23. Gao F, Vasqiez SX, Su F, Roberts S, Shah N, Grijalva V, et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Inteqr Biol (Camb) 2011; 3:479-89.
24. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400. (Pubitemid 36578475)
25. Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535-40. (Pubitemid 34615160)
26. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 2002 19;287:3081-2.
27. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1185-91. (Pubitemid 38917907)
28. Nicotera TM, Privalle C, Wang TC, Oshimura M, Barrett JC. Differential proliferative responses of Syrian hamster embryo fibroblasts to paraquat-generated superoxide radicals depending on tumor suppressor gene function. Cancer Res 1994;54: 3884-8. (Pubitemid 24241211)
29. Loo G. Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation (review). J Nutr Biochem 2003; 14:64-73. (Pubitemid 36349516)
30. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, et al. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 2005;280:39485-92. (Pubitemid 41713906)
31. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stöckl J. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010;12:1009-59.
32. Wang L, Gill R, Pedersen TL, Higgins LJ, Newman JW, Rutledge JC. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res 2009;50:204-13.
33. James RW, Deakin SP. The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function. Adv Exp Med Biol 2010;660:173-81.
34. Getz GS, Wool GD, Reardon CA. Biological properties of apolipoprotein a-1 mimetic peptides. Curr Atheroscler Rep 2010;12:96-104.
35. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010;18:141-7.
36. Getz GS, Wool GD, Reardon CA. Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr Opin Lipidol 2009;20:171-5.
37. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, et al. Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 2009;11:52-7.
38. Navab M, Anantharamaiah GM, Fogelman AM. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med 2008;18:61-6. (Pubitemid 351282495)
39. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, et al. Potential clinical utility of high-density lipoproteinmimetic peptides. Curr Opin Lipidol 2006;17:440-4. (Pubitemid 44079483)
40. Reddy ST, Anantharamaiah GM, Navab M, Hama S, Hough G, Grijalva V, et al. Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 2006;15:13-21. (Pubitemid 43034148)
41. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 2011;130: 1071-81.
42. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, et al. An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005;25: 1932-7. (Pubitemid 41243465)
43. Bloedon LT, Dunbar R, Duff D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008;49:1344-52.
44. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011;52:361-73.
45. Navab M, Reddy T, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, et al. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 2011;52:1200-10.
46. Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010;161:241-70.